Virus-based nanoparticles as platform technologies for modern vaccines

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 8, Issue 4, 2016, Pages 554-578

  Lee, Karin L ^a   Twyman, Richard M ^b   Fiering, Steven ^c   Steinmetz, Nicole F ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TRM Ltd   (United Kingdom)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLES; VACCINES; VIRUSES;

CELLULAR TARGETS; CHRONIC DISEASE; INFECTIOUS DISEASE; MULTIPLE PATHWAYS; NANOPARTICLE SYSTEMS; NANOSCAFFOLDS; NANOSCALE ENGINEERING; PLATFORM TECHNOLOGY;

DISEASES;

CHEMOKINE RECEPTOR CCR5; COAT PROTEIN; COCAINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MATRIX PROTEIN; MOLECULAR SCAFFOLD; NANOPARTICLE; NICOTINE; NICOTINE VACCINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VACCINE; VIROSOME;

ADDICTION; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BREAST CANCER; CELL MEDIATED CYTOTOXICITY; CHEMICAL ENGINEERING; CHRONIC DISEASE; CONJUGATION; GENETIC DRIFT; GENETIC ENGINEERING; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOTHERAPY; LIVER CELL CARCINOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; UTERINE CERVIX CANCER; VIRUS ASSEMBLY;

EID: 84975089486     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1383     Document Type: Review

References (201)

1. Clem AS . Fundamentals of vaccine immunology. J Global Infect Dis 2011, 3:73–78.
2. Pulendran B, Ahmed R . Immunological mechanisms of vaccination. Nat Immunol 2011, 12:509–517.
3. Riedel S . Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005, 18:21–25.
4. Miller M, Barrett S, Henderson DA . Control and eradication. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, eds. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006.
5. Knobler S, Lederberg J, Pray LA, eds. Considerations for Viral Disease Eradication: Lessons Learned and Future Strategies: Workshop Summary. Washington, DC: The National Academies Press; 2002.
6. Hicks DJ, Fooks AR, Johnson N . Developments in rabies vaccines. Clin Exp Immunol 2012, 169:199–204.
7. Geier MR, Geier DA, Zahalsky AC . A review of hepatitis B vaccination. Expert Opin Drug Saf 2003, 2:113–122.
8. Lopez AL, Gonzales ML, Aldaba JG, Nair GB . Killed oral cholera vaccines: history, development and implementation challenges. Ther Adv Vaccines 2014, 2:123–136.
9. Scorpio A, Blank TE, Day WA, Chabot DJ . Anthrax vaccines: Pasteur to the present. Cell Mol Life Sci 2006, 63:2237–2248.
10. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP . Nanoparticle vaccines. Vaccine 2014, 32:327–337.
11. Gregory AE, Titball R, Williamson D . Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013, 3:13.
12. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP . Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 2014, 111:425–440.
13. Jennings GT, Bachmann MF . The coming of age of virus-like particle vaccines. Biol Chem 2008, 389:521–536.
14. Peacey M, Wilson S, Baird MA, Ward VK . Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnol Bioeng 2007, 98:968–977.
15. Zhang W, Wang L, Liu Y, Chen X, Liu Q, Jia J, Yang T, Qiu S, Ma G . Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 2014, 35:6086–6097.
16. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S . Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526–1529.
17. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF . TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007, 178:2415–2420.
18. Bessa J, Jegerlehner A, Hinton HJ, Pumpens P, Saudan P, Schneider P, Bachmann MF . Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol 2009, 183:3788–3799.
19. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL . Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 2011, 34:375–384.
20. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q . Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 2009, 32:118–128.
21. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF . Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404–1413.
22. Vogel FR . Improving vaccine performance with adjuvants. Clin Infect Dis 2000, 30(Suppl 3):S266–S270.
23. Goldman MaL P-H . Immunological safety of vaccines: facts, hypotheses, and allegation. In: Kaufmann SHE, ed. Novel Vaccination Strategies. Germany: Wiley-VCH; 2004, 595–611.
24. Schneemann A, Young MJ . Viral assembly using heterologous expression systems and cell extracts. Adv Protein Chem 2003, 64:1–36.
25. Pokorski JK, Steinmetz NF . The art of engineering viral nanoparticles. Mol Pharm 2011, 8:29–43.
26. Shukla S, Dickmeis C, Nagarajan AS, Fischer R, Commandeur U, Steinmetz NF . Molecular farming of fluorescent virus-based nanoparticles for optical imaging in plants, human cells and mouse models. Biomater Sci 2014, 2:784–797.
27. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, Benvenuto E, Capone I . Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 2001, 75:8434–8439.
28. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V, Jennings GT, Saudan P, Pumpens P, Bachmann MF . Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010, 5:e9809.
29. Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill LK . Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (N Y) 1995, 13:53–57.
30. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, Lecours K, Bolduc M, Pare C, Willems B, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007, 363:59–68.
31. Tremblay MH, Majeau N, Gagne ME, Lecours K, Morin H, Duvignaud JB, Bolduc M, Chouinard N, Pare C, Gagne S, et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J 2006, 273:14–25.
32. Phelps JP, Dang N, Rasochova L . Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis . J Virol Methods 2007, 141:146–153.
33. O'Neil A, Prevelige PE, Basu G, Douglas T . Coconfinement of fluorescent proteins: spatially enforced communication of GFP and mCherry encapsulated within the P22 capsid. Biomacromolecules 2012, 13:3902–3907.
34. Patterson DP, Rynda-Apple A, Harmsen AL, Harmsen AG, Douglas T . Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 2013, 7:3036–3044.
35. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD . Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’. J Gen Virol 2001, 82:1013–1025.
36. Pastori C, Tudor D, Diomede L, Drillet AS, Jegerlehner A, Rohn TA, Bomsel M, Lopalco L . Virus like particle based strategy to elicit HIV-protective antibodies to the α-helic regions of gp41. Virology 2012, 431:1–11.
37. Chackerian B, Lowy DR, Schiller JT . Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 1999, 96:2373–2378.
38. Van Rompay KK, Hunter Z, Jayashankar K, Peabody J, Montefiori D, LaBranche CC, Keele BF, Jensen K, Abel K, Chackerian B . A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol 2014, 88:2011–2024.
39. Adis International L. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D 2003, 4:249–253.
40. Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, Kintu K, Emel L, Musoke P, Fowler MG, et al. Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. J Acquir Immune Defic Syndr 2014, 65:268–277.
41. McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, McNamara J, Read JS, Douglas SD, Deville J, Gurwith M, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006, 20:1481–1489.
42. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011, 6:e27837.
43. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209–2220.
44. Dunkel A, Shen S, LaBranche CC, Montefiori D, McGettigan JP . A bivalent, chimeric Rabies virus expressing simian immunodeficiency virus envelope induces multifunctional antibody responses. AIDS Res Hum Retroviruses 2015, 31:1126–1138.
45. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269–280.
46. Martins KA, Steffens JT, van Tongeren SA, Wells JB, Bergeron AA, Dickson SP, Dye JM, Salazar AM, Bavari S . Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS One 2014, 9:e89735.
47. Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C . Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006, 351:260–270.
48. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S . Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(Suppl 2):S430–S437.
49. Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y . Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science 2015, 348:439–442.
50. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015, 386:857–866.
51. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011, 85:10605–10616.
52. Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis 2015, 212:S414–S424.
53. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM . Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83:5726–5734.
54. Liu YV, Massare MJ, Pearce MB, Sun X, Belser JA, Maines TR, Creager HM, Glenn GM, Pushko P, Smith GE, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine 2015, 33:2152–2158.
55. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29:7826–7834.
56. Ward BJ, Landry N, Trepanier S, Mercier G, Dargis M, Couture M, D'Aoust MA, Vezina LP . Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 2014, 32:6098–6106.
57. Ren Z, Ji X, Meng L, Wei Y, Wang T, Feng N, Zheng X, Wang H, Li N, Gao X, et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus. Virus Res 2015, 200:9–18.
58. Chen S, Zheng D, Li C, Zhang W, Xu W, Liu X, Fang F, Chen Z . Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. Biomed Res Int 2015, 2015:901817.
59. Naskalska A, Szolajska E, Chaperot L, Angel J, Plumas J, Chroboczek J . Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron. Vaccine 2009, 27:7385–7393.
60. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395–3403.
61. Pascual E, Mata CP, Gomez-Blanco J, Moreno N, Barcena J, Blanco E, Rodriguez-Frandsen A, Nieto A, Carrascosa JL, Caston JR . Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity. J Virol 2015, 89:2563–2574.
62. Babin C, Majeau N, Leclerc D . Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. J Nanobiotechnol 2013, 11:10.
63. Lico C, Mancini C, Italiani P, Betti C, Boraschi D, Benvenuto E, Baschieri S . Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. Vaccine 2009, 27:5069–5076.
64. Richert LE, Servid AE, Harmsen AL, Rynda-Apple A, Han S, Wiley JA, Douglas T, Harmsen AG . A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 2012, 30:3653–3665.
65. Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, Randall TD, Jutila M, Douglas T, Broomell C, Young M, et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One 2009, 4:e7142.
66. Yin Z, Nguyen HG, Chowdhury S, Bentley P, Bruckman MA, Miermont A, Gildersleeve JC, Wang Q, Huang X . Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens. Bioconjug Chem 2012, 23:1694–1703.
67. Yin Z, Comellas-Aragones M, Chowdhury S, Bentley P, Kaczanowska K, Benmohamed L, Gildersleeve JC, Finn MG, Huang X . Boosting immunity to small tumor-associated carbohydrates with bacteriophage qβ capsids. ACS Chem Biol 2013, 8:1253–1262.
68. McCormick AA, Corbo TA, Wykoff-Clary S, Palmer KE, Pogue GP . Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. Bioconjug Chem 2006, 17:1330–1338.
69. Jobsri J, Allen A, Rajagopal D, Shipton M, Kanyuka K, Lomonossoff GP, Ottensmeier C, Diebold SS, Stevenson FK, Savelyeva N . Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. PLoS One 2015, 10:e0118096.
70. Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I . Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother 2010, 59:1685–1696.
71. Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B . VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 2012, 7:e49751.
72. Tyler M, Tumban E, Peabody DS, Chackerian B . The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnol Bioeng 2014, 111:2398–2406.
73. Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R . A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic α-7 human papillomavirus types. PLoS One 2015, 10:e0120152.
74. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschroder B, Grubert T, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007, 121:2794–2800.
75. Monroy-Garcia A, Gomez-Lim MA, Weiss-Steider B, Hernandez-Montes J, Huerta-Yepez S, Rangel-Santiago JF, Santiago-Osorio E, Mora Garcia Mde L . Immunization with an HPV-16L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch Virol 2014, 159:291–305.
76. Ding FX, Wang F, Lu YM, Li K, Wang KH, He XW, Sun SH . Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009, 49:1492–1502.
77. Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, Bartsch R, Steger G, Pehamberger H, Scheiner O, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2010, 119:673–683.
78. Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, et al. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomedicine 2015, 11:1097–1107.
79. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T . A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005, 65:5953–5957.
80. Pouyanfard S, Bamdad T, Hashemi H, Bandehpour M, Kazemi B . Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles. PLoS One 2012, 7:e49539.
81. Shukla S, Wen AM, Commandeur U, Steinmetz NF . Presentation of HER2 epitopes using a filamentous plant virus-based vaccination platform. J Mater Chem B 2014, 2:6249–6258.
82. Montoya ID . Biologics (vaccines, antibodies, enzymes) to treat drug addictions. In: Nady el-Guebaly GC, Galanter M, eds. Textbook of Addiction Treatment: International Perspectives. New York: Springer; 2015, 683–692.
83. De BP, Pagovich OE, Hicks MJ, Rosenberg JB, Moreno AY, Janda KD, Koob GF, Worgall S, Kaminsky SM, Sondhi D, et al. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Hum Gene Ther 2013, 24:58–66.
84. Hicks MJ, De BP, Rosenberg JB, Davidson JT, Moreno AY, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 2011, 19:612–619.
85. Wee S, Hicks MJ, De BP, Rosenberg JB, Moreno AY, Kaminsky SM, Janda KD, Crystal RG, Koob GF . Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 2012, 37:1083–1091.
86. Chackerian B, Rangel M, Hunter Z, Peabody DS . Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine 2006, 24:6321–6331.
87. Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, Caputo A, Winblad B, Graf A . Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther 2015, 7:23.
88. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012, 11:597–604.
89. Feng G, Wang W, Qian Y, Jin H . Anti-Aβ antibodies induced by Aβ-HBc virus-like particles prevent Aβ aggregation and protect PC12 cells against toxicity of Aβ1-40. J Neurosci Methods 2013, 218:48–54.
90. Zamora E, Handisurya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC, Kirnbauer R . Papillomavirus-like particles are an effective platform for amyloid-β immunization in rabbits and transgenic mice. J Immunol 2006, 177:2662–2670.
91. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT . The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008, 6:143–155.
92. Maartens G, Celum C, Lewin SR . HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014, 384:258–271.
93. Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B . The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage 2001, 21:41–51.
94. Esparza J . A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013, 31:3502–3518.
95. Dowdle W . The search for an AIDS vaccine. Public Health Rep 1986, 101:232–233.
96. Buratti E, Tisminetzky SG, Scodeller ES, Baralle FE . Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein. J Immunol Methods 1996, 197:7–18.
97. Berkower I, Raymond M, Muller J, Spadaccini A, Aberdeen A . Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology 2004, 321:75–86.
98. Sun S, Li W, Sun Y, Pan Y, Li J . A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae . Biochem Biophys Res Commun 2011, 407:124–128.
99. Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, Hooper DC, Koprowski H . Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci USA 1997, 94:5784–5788.
100. Sugiyama Y, Hamamoto H, Takemoto S, Watanabe Y, Okada Y . Systemic production of foreign peptides on the particle surface of tobacco mosaic virus. FEBS Lett 1995, 359:247–250.
101. Lu Y, Xiao Y, Ding J, Dierich M, Chen YH . Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1. Int Arch Allergy Immunol 2000, 121:80–84.
102. Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, Phung P, Tian Y, Resnick DA, Ma X, Mariano TM, et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009, 83:5087–5100.
103. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA . CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955–1958.
104. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135–1148.
105. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661–666.
106. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW . A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149–1158.
107. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667–673.
108. Park DJ, Dudas G, Wohl S, Goba A, Whitmer SL, Andersen KG, Sealfon RS, Ladner JT, Kugelman JR, Matranga CB, et al. Ebola virus epidemiology, transmission, and evolution during seven months in sierra leone. Cell 2015, 161:1516–1526.
109. Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC . Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med 2014, 72:442–448.
110. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keita S, De Clerck H, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014, 371:1418–1425.
111. Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, et al. Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus. J Infect Dis 2015, 212:S443–S451.
112. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H . Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007, 196(Suppl 2):S404–S412.
113. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2.
114. Geisbert TW, Feldmann H . Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011, 204(Suppl 3):S1075–S1081.
115. de Wit E, Marzi A, Bushmaker T, Brining D, Scott D, Richt JA, Geisbert TW, Feldmann H . Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis 2015, 21:702–704.
116. Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE . Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 2012, 30:6136–6141.
117. World Health Organization. Influenza (Seasonal) Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/.
118. Lambert LC, Fauci AS . Influenza vaccines for the future. N Engl J Med 2010, 363:2036–2044.
119. Krammer F . Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J 2015, 10:690–701.
120. Taubenberger JK, Morens DM . Influenza: the once and future pandemic. Public Health Rep 2010, 125(Suppl 3):16–26.
121. World Health Organization Global Influenza Program Surveillance N. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005, 11:1515–1521.
122. Riedel S . Crossing the species barrier: the threat of an avian influenza pandemic. Proc (Bayl Univ Med Cent) 2006, 19:16–20.
123. Fiore AE, Bridges CB, Cox NJ . Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009, 333:43–82.
124. Krammer F, Palese P . Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013, 3:521–530.
125. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD . Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61:94–99.
126. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M . Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 2013, 11:153.
127. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG . Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991, 65:5491–5498.
128. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ . Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404–5410.
129. Kawano M, Morikawa K, Suda T, Ohno N, Matsushita S, Akatsuka T, Handa H, Matsui M . Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. Virology 2014, 448:159–167.
130. Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, Klonowski KD, Lefrancois L, Cauley LS, Harmsen AG, Lund FE, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 2006, 25:643–654.
131. D'Aoust MA, Lavoie PO, Couture MM, Trepanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vezina LP . Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008, 6:930–940.
132. Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000, 100:57–70.
133. Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, Fiering S . In situvaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol 2015. doi: 10.1038/nnano.2015.292
134. American Cancer Society. Global Cancer Facts & Figures. 3rd ed. Atlanta, GA: American Cancer Society, Inc.; 2015.
135. Castellsague X, Bosch FX . Advances in cervical cancer prevention: HPV vaccines. Farm Hosp 2007, 31:261–263.
136. Bosch FX, de Sanjose S . The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007, 23:213–227.
137. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991–998.
138. Stanley M . Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010, 117:S5–S10.
139. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89–99.
140. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325–339.
141. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009, 199:926–935.
142. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009, 199:936–944.
143. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT . Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3:109–115.
144. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT . Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254–257.
145. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB . A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007, 81:13927–13931.
146. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB . Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337:365–372.
147. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R . Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 2013, 133:2706–2713.
148. Karanam B, Jagu S, Huh WK, Roden RB . Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009, 87:287–299.
149. Tumban E, Peabody J, Peabody DS, Chackerian B . A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011, 6:e23310.
150. zur Hausen H . Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92:690–698.
151. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L . Chimeric papillomavirus-like particles. Virology 1997, 234:93–111.
152. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I . Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999, 81:881–888.
153. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Muller RT, Jochmus I, Gissmann L, Schneider A, et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001, 92:285–293.
154. Ohlschlager P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Muller M, Pawlita M, Schafer K, Sehr P, et al. Human papillomavirus type 16L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003, 77:4635–4645.
155. London WT, McGlynn KA . Liver cancer. In: Schottenfeld DFJJ, Fraumeni JFJ, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006, 763–786.
156. Mittal S, El-Serag HB . Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013, 47(Suppl):S2–S6.
157. El-Serag HB . Hepatocellular carcinoma. N Engl J Med 2011, 365:1118–1127.
158. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR . Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307:178–180.
159. Andre FE, Safary A . Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J 1987, 63(Suppl 2):169–177.
160. Su F, Schneider RJ . Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor α. Proc Natl Acad Sci USA 1997, 94:8744–8749.
161. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869–10874.
162. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN . The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320–368.
163. Jhaveri K, Esteva FJ . Pertuzumab in the treatment of HER2+ breast cancer. J Natl Compr Canc Netw 2014, 12:591–598.
164. Hortobagyi GN . Trastuzumab in the treatment of breast cancer. N Engl J Med 2005, 353:1734–1736.
165. Zurbriggen R . Immunostimulating reconstituted influenza virosomes. Vaccine 2003, 21:921–924.
166. Bovier PA . Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008, 7:1141–1150.
167. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008, 3:e1493.
168. Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U . Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 2007, 106:29–38.
169. Chen XS, Stehle T, Harrison SC . Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J 1998, 17:3233–3240.
170. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD . Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378:727–730.
171. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996, 2:1129–1132.
172. Kinsey BM, Jackson DC, Orson FM . Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009, 87:309–314.
173. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Muller P, Bachmann MF . A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005, 35:2031–2040.
174. Maoz A, Hicks MJ, Vallabhjosula S, Synan M, Kothari PJ, Dyke JP, Ballon DJ, Kaminsky SM, De BP, Rosenberg JB, et al. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacology 2013, 38:2170–2178.
175. Bachmann MF, Jennings GT . Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci 2011, 366:2815–2822.
176. Chackerian B, Lowy DR, Schiller JT . Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001, 108:415–423.
177. Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF . Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 2008, 38:877–887.
178. Spohn G, Bachmann MF . Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL. Adv Exp Med Biol 2007, 602:135–142.
179. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, Rohner F, Bauer M, Dietmeier K, Kundig TM, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007, 178:7450–7457.
180. Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, Kopf M, Bachmann MF . Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006, 36:2857–2867.
181. Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, Bachmann MH, Contag CH, Fathman CG . Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001, 107:1293–1301.
182. Spohn G, Schwarz K, Maurer P, Illges H, Rajasekaran N, Choi Y, Jennings GT, Bachmann MF . Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 2005, 175:6211–6218.
183. Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, Bachmann MF, Kopf M . Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006, 36:2849–2856.
184. Fulurija A, Lutz TA, Sladko K, Osto M, Wielinga PY, Bachmann MF, Saudan P . Vaccination against GIP for the treatment of obesity. PLoS One 2008, 3:e3163.
185. Chackerian B . Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6:381–390.
186. Bachmann MF, Whitehead P . Active immunotherapy for chronic diseases. Vaccine 2013, 31:1777–1784.
187. Jennings GT, Bachmann MF . Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009, 49:303–326.
188. Ambuhl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63–72.
189. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Muller P, Jennings GT, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821–827.
190. Liebscher S, Meyer-Luehmann M . A peephole into the brain: neuropathological features of Alzheimer's disease revealed by in vivo two-photon imaging. Front Psychiatry 2012, 3:26.
191. Hardy JA, Higgins GA . Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184–185.
192. Haass C, Selkoe DJ . Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell 1993, 75:1039–1042.
193. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173–177.
194. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916–919.
195. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003, 61:46–54.
196. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO . Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003, 9:448–452.
197. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F . Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol 2004, 14:11–20.
198. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003, 100:2023–2028.
199. Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA . Species-specific immune response to immunization with human versus rodent A β peptide. Neurobiol Aging 2004, 25:1141–1151.
200. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Luond R, Ortmann R, Reichwald J, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011, 31:9323–9331.
201. Karpenko LI, Ivanisenko VA, Pika IA, Chikaev NA, Eroshkin AM, Veremeiko TA, Ilyichev AA . Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18:329–337.